Binding Site Offers Family of Recombinant Parvovirus Antigens
Eight new recombinant Parvovirus antigens added to the company's broad offering of products
Binding Site’s IMMUNOLOGICALS GROUP is pleased to announce the addition of eight new recombinant Parvovirus antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. The Parvovirus NS1; Parvovirus PepA (VP1 unique); Parvovirus PepB (VP2 C-term.); Parvovirus PepC (VP1 N-term.); Parvovirus PepD (VP1 C-term.); Parvovirus VP1; Parvovirus VP2; and Parvovirus VP2 VLP antigens, have been expressly designed for use as integral components within solid phase enzyme immunoassay test procedures, especially ELISA. As such, the availability of these two antigens will benefit the needs of biopharmaceutical, clinical, drug-discovery, and life science researchers, as well as manufacturers of IVD test kits.
All of the antigens offered are E coli source-derived recombinant proteins which exhibit exceptional purity levels as a result of exclusive chromatographic manufacturing techniques, while demonstrating exceptional lot-to-lot consistencies and high degrees of activity and specificity. They all feature an outstanding shelf life stability claim of 10 years from the date of manufacture and are offered in a standard-sized 1.0mg filled vial, with larger, bulk packaging configurations also being available.